IARTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
INTEGRA LIFESCIENCES HOLDINGS CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$13.45+0.24 (+1.82%)
Close on Oct 19, 2026
- Market cap
- $1.05B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.63 (−10.81%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
INTEGRA LIFESCIENCES HOLDINGS CORP grew revenue 1.6% to $1.65B over the twelve months to Jun 30, 2026. Free cash flow was $25.80M.
Revenue
$1.65B
+1.6% vs. a year earlier
Operating income
$65.56M
TTM Q2 2026
Free cash flow
$25.80M
TTM Q2 2026
EPS, diluted
-$0.09
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.05B
- P/E ratio
- –
- Price to sales
- 0.64
- Price to book
- 1.01
- Dividend yield
- –
- Free cash flow yield
- 2.45%
Fundamentals
- Revenue
- $1.65B
- Net income
- -$7.24M
- EPS, diluted
- -$0.09
- Free cash flow
- $25.80M
- Book value per share
- $13.35
- Diluted shares
- 78M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$1.65B+1.6% YoY
Gross profit
$864.58M+1.3% YoY
Operating income
$65.56M
Net income
-$7.24M
EPS, diluted
-$0.09
Free cash flow
$25.80M
Reported periodTrailing twelve months